XML 21 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
Series A
Preferred Stock
Common Stock
Additional Paid-in- Capital
Reserves
Accumulated Other Comprehensive Income/(Loss)
Accumulated Deficit
Total Mawson Stockholders’ Equity
Non- controlling interest
Common Shares
Share Subscription Receivable
Total
Balance at Dec. 31, 2020     $ 34,457,051 $ 652,949 $ (1,341,826) $ (26,159,539) $ 7,591,945 $ (27,066)   $ (16,690) $ 7,564,879
Balance (in Shares) at Dec. 31, 2020                 7,539,275    
Balance at Dec. 31, 2021   $ 611,504 165,600,831 20,177,233 (521,094) (71,123,259) 114,745,215 (164,626)     114,580,589
Balance (in Shares) at Dec. 31, 2021   11,791,085                  
Issuance of common stock, stock based compensation   $ 4,140 358,104 5,782,051     6,144,295       6,144,295
Issuance of common stock, stock based compensation (in Shares)   33,154                  
Issuance of common stock, settlement of convertible note interest   $ 8,691 851,680       860,371       860,371
Issuance of common stock, settlement of convertible note interest (in Shares)   14,493                  
Exchange of stock and Reverse recapitalization of Wize Pharma Inc   $ 511,882 (5,436,541)       (4,924,659)       (4,924,659)
Exchange of stock and Reverse recapitalization of Wize Pharma Inc (in Shares) 178 8,531,361             (7,539,275)    
Issuance of common stock, net of offer costs, PIPE transaction $ 25,000 2,975,000       3,000,000     3,000,000
Issuance of common stock, net of offer costs, PIPE transaction (in Shares)   416,667                  
Issuance of convertible notes, net of offer costs   20,301,427 20,301,427       20,301,427
Issuance of warrants   (7,571,740) 16,817,286 9,245,546     9,245,546
Issuance of common stock, net of offering costs / at-the market offerings   $ 8,592 74,912,708       74,921,300       74,921,300
Issuance of common stock, net of offering costs / at-the market offerings (in Shares)   1,437,094                  
Fair value of IPR&D acquired, net of Business Combination transaction costs     24,765,831       24,765,831       24,765,831
Fair value adjustment of LO2A intellectual property revenue sharing obligation     5,440,863       5,440,863       5,440,863
Issuance of RSU’s and stock options     890,251 10,332,552     11,222,803       11,222,803
Issuance of common stock, conversion of Series A preferred stock (in Shares) (178) 2,967                  
Issuance of common stock, on conversion of convertible notes   $ 63,627         63,627       63,627
Issuance of common stock, on conversion of convertible notes (in Shares)   1,060,448                  
Issuance of common stock, exercise of warrants   $ 1,820 13,468,875 (13,346,668)     124,027       124,027
Issuance of common stock, exercise of warrants (in Shares)   290,808                  
Issuance of stock by subsidiary to non-controlling interest     406,534       406,534 511,150     917,684
Purchase remaining non-controlling interest of Luna Squares LLC     (241,713)       (241,713) (150,766)     (392,479)
Exercise of RSU’s   $ 24 60,913 (60,937)              
Exercise of RSU’s (in Shares)   4,063                  
Other   $ (12,272) (38,412)       (33,994)     $ 16,690 (33,994)
Other (in Shares)   30                  
Net loss           (44,963,720) (44,963,720) (497,944)     (45,461,664)
Other comprehensive income         820,732   820,732       820,732
Balance at Dec. 31, 2022   $ 613,977 166,489,846 27,204,362 5,021,467 (122,257,628) 77,072,024 (905,904)     76,166,120
Balance (in Shares) at Dec. 31, 2022   13,625,882                  
Issuance of common stock, stock based compensation   $ 19 134,880 408,584 543,483     543,483
Issuance of common stock, stock based compensation (in Shares)   3,131                  
Issuance of warrants   (10,243,200) 11,911,533 1,668,333     1,668,333
Issuance of RSU’s and stock options   $ 2,454 6,037,506 (5,292,988) 746,972     $ 746,972
Issuance of RSU’s and stock options (in Shares)   410,165                  
Exercise of RSU’s (in Shares)                     212,667
Issuance of common stock, net of offer costs   5,877,513 5,877,513     $ 5,877,513
Issuance of common stock, net of offer costs (in Shares)   1,421,501                  
Net loss   (52,762,308) (52,762,308) (1,273,251)     (54,035,559)
Other comprehensive income   5,542,561 5,542,561 (2,046)     5,540,515
Non-controlling interest   $ (917,684) $ 1,627,939 $ 710,255 $ 534,019     $ 1,244,274